Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and MedinCell have released positive results from the TV46000-CNS-30072 study. The Risperidone Subcutaneous Extended-Release Study (RISE) is a third phase clinical study designed to assess TV-46000/mdc-IRM as a schizophrenia treatment. Risperidone injection delays relapse in schizophrenia patients Enrolment for the study was open to schizophrenic […]